Pulmatrix Shares Outstanding 2014-2022 | PULM
Pulmatrix shares outstanding from 2014 to 2022. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Pulmatrix Annual Shares Outstanding (Millions of Shares) |
2021 |
3 |
2020 |
1 |
2019 |
1 |
2018 |
0 |
2017 |
0 |
2016 |
0 |
2015 |
0 |
2014 |
0 |
2014 |
0 |
2013 |
|
2013 |
0 |
2012 |
0 |
Pulmatrix Quarterly Shares Outstanding (Millions of Shares) |
2022-09-30 |
3 |
2022-06-30 |
3 |
2022-03-31 |
3 |
2021-12-31 |
3 |
2021-09-30 |
3 |
2021-06-30 |
3 |
2021-03-31 |
2 |
2020-12-31 |
1 |
2020-09-30 |
2 |
2020-06-30 |
1 |
2020-03-31 |
1 |
2019-12-31 |
1 |
2019-09-30 |
1 |
2019-06-30 |
1 |
2019-03-31 |
0 |
2018-12-31 |
0 |
2018-09-30 |
0 |
2018-06-30 |
0 |
2018-03-31 |
0 |
2017-12-31 |
0 |
2017-09-30 |
0 |
2017-06-30 |
0 |
2017-03-31 |
0 |
2016-12-31 |
0 |
2016-09-30 |
0 |
2016-06-30 |
0 |
2016-03-31 |
0 |
2015-12-31 |
0 |
2015-09-30 |
0 |
2015-06-30 |
0 |
2015-03-31 |
0 |
2014-12-31 |
0 |
2014-09-30 |
0 |
2014-06-30 |
0 |
2014-03-31 |
0 |
2013-12-31 |
0 |
2013-09-30 |
0 |
2013-06-30 |
0 |
2013-03-31 |
0 |
Sector |
Industry |
Market Cap |
Revenue |
Medical |
Medical - Biomedical and Genetics |
$0.015B |
$0.005B |
Pulmatrix, Inc. is a biopharmaceutical company which is engaged in developing inhaled therapies for serious pulmonary disease. The Company's proprietary product pipeline includes PUR1900, an inhaled anti-fungal for cystic fibrosis, PUR0200, a branded generic for chronic obstructive pulmonary disease which are in different clinical stage. Its technology platform consists of iSPERSE. Pulmatrix, Inc., formerly known as Ruthigen, Inc., is based in Lexington, MA.
|